Page of

Small cell lung cancer (SCLC) and syndrome of inappropriate antidiurectic hormone (SIADH): Small cell lung cancer (SCLC) and syndrome of inappropriate antidiurectic hormone (SIADH) Expert commentary Angela Darby Expert commentary Angela Darby 

Small cell lung cancer (SCLC) and syndrome of inappropriate antidiurectic hormone (SIADH): Small cell lung cancer (SCLC) and syndrome of inappropriate antidiurectic hormone (SIADH) Expert commentary Angela Darby Expert commentary Angela Darby
Chapter:
Small cell lung cancer (SCLC) and syndrome of inappropriate antidiurectic hormone (SIADH): Expert commentary Angela Darby
Source:
Challenging Concepts in Oncology
Author(s):

Alex Lee

DOI:
10.1093/med/9780199688883.003.0004

Small cell lung cancer (SCLC) is a smoking-associated malignancy. Accounting for 15-20% of lung cancers, the onset is typically rapid. In localized disease, surgical resection can be considered. High rates of response to first-line chemotherapy are seen, with the addition of concurrent radiotherapy improving survival in disease restricted to the ipsilateral hemithorax, as illustrated by this case. Prophylactic cranial irradiation, following response to induction therapy, reduces the rate of brain metastases and prolongs survival. Disease relapse occurs in a large proportion of cases, frequently within 1 year of induction treatment. Second-line options have a modest impact, in terms of response and survival. So far, there has been limited success of novel targeted agents in the treatment of SCLC treatment. This case discusses the recurrence of SCLC with the syndrome of inappropriate anti-diuretic hormone (SIADH) secretion. It is the cancer most commonly associated with paraneoplastic endocrine and neurological syndromes.

Sign In

Copyright © 2020. All rights reserved.